GlassScriptPhysician profile
Rafael Miguel Vaquer
NPI 1316492796
$1,830.76
in general payments reported to CMS, 2019-2025
14 companies · $554 in 2025
The $554 reported for 2025 was more than what 80% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.51 · 2022: $115 · 2023: $517 · 2024: $591 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,662.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ns Pharma, INC. | $504.82 | 2023-2025 | Viltepso |
| Alexion Pharmaceuticals, INC. | $379.26 | 2023-2025 | Ultomiris |
| Argenx US, INC. | $124.95 | 2024 | Vyvgart |
| Ucb, INC. | $124.92 | 2023 | |
| Genentech USA, INC. | $124.32 | 2023 | Evrysdi |
| Genzyme Corporation | $114.90 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $104.31 | 2025 | |
| Emd Serono, INC. | $102.42 | 2024 | Mavenclad |
| Tonix Medicines, INC. | $67.35 | 2025 | Tonmya |
| Ipsen Biopharmaceuticals, INC | $53.51 | 2019 | |
| Abbvie INC. | $43.19 | 2023-2025 | Qulipta |
| Ptc Therapeutics, INC. | $37.61 | 2024 | Emflaza |
| Sarepta Therapeutics, INC. | $33.41 | 2024 | Elevidys |
| Biogen, INC. | $15.79 | 2024 | Vumerity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Vaquer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.